At day two following the end of therapy, the fasting insulin levels of the patients in the FH+ DM group and FH- DM group were lower compared with the value prior to therapy (FH+ DM group, 8.69±3.22 vs. 10.49±6.14 mIU/l; FH- DM group, 8.46±3.55 vs. 10.01±6.47 mIU/l; P=0.013 and 0.022, respectively), while the first-phase peak ratios in the two groups were higher than the value prior to treatment (FH+ DM group, 5.75±2.04 vs. 5.03±2.51; FH- DM group, 6.17±2.42 vs. 5.23±2.47; P=0.037 and 0.042, respectively). The gene discussed is INS; the disease is diabetes mellitus.